This bifunctional degrader, composed of lapatinib linked to a VHL ligand, potently induces the degradation of wild-type EGFR (DC50 = 39.2 nM in OVCAR8) and HER2, and is active against Exon20Ins mutant EGFR. It inhibits proliferation in HER2-driven breast cancer models like SKBr3 cells (IC50 = 102 nM), supporting its use in targeted protein degradation research for oncology.